| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flow Cytometry | 39 | 2024 | 1173 | 6.990 |
Why?
|
| Single-Cell Analysis | 16 | 2025 | 359 | 4.200 |
Why?
|
| Germinal Center | 6 | 2022 | 67 | 1.900 |
Why?
|
| Signal Transduction | 24 | 2025 | 5233 | 1.570 |
Why?
|
| Glioblastoma | 3 | 2023 | 353 | 1.480 |
Why?
|
| Neoplasms | 11 | 2022 | 2884 | 1.450 |
Why?
|
| Unsupervised Machine Learning | 2 | 2021 | 22 | 1.320 |
Why?
|
| B-Lymphocytes | 6 | 2022 | 877 | 1.290 |
Why?
|
| Myeloid-Derived Suppressor Cells | 4 | 2021 | 72 | 1.290 |
Why?
|
| Melanoma | 5 | 2022 | 761 | 1.250 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2023 | 683 | 1.240 |
Why?
|
| Lymphoma, Follicular | 8 | 2017 | 56 | 1.210 |
Why?
|
| Monocytes | 5 | 2022 | 538 | 1.170 |
Why?
|
| Immunophenotyping | 10 | 2024 | 322 | 1.150 |
Why?
|
| Monitoring, Immunologic | 2 | 2018 | 23 | 1.060 |
Why?
|
| Mass Spectrometry | 5 | 2019 | 750 | 1.050 |
Why?
|
| Receptors, Antigen, B-Cell | 6 | 2022 | 134 | 0.940 |
Why?
|
| Image Cytometry | 3 | 2022 | 12 | 0.940 |
Why?
|
| Benzofurans | 1 | 2025 | 26 | 0.910 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 192 | 0.910 |
Why?
|
| Biological Products | 3 | 2025 | 252 | 0.900 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2017 | 84 | 0.870 |
Why?
|
| Dendritic Cells | 2 | 2019 | 499 | 0.840 |
Why?
|
| Otolaryngology | 2 | 2017 | 108 | 0.820 |
Why?
|
| Macrophages | 3 | 2023 | 1511 | 0.760 |
Why?
|
| Machine Learning | 3 | 2018 | 587 | 0.740 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 573 | 0.690 |
Why?
|
| Phagocytes | 2 | 2019 | 81 | 0.670 |
Why?
|
| Humans | 97 | 2026 | 144957 | 0.670 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 50 | 0.660 |
Why?
|
| Brain Neoplasms | 2 | 2023 | 1322 | 0.660 |
Why?
|
| Proteomics | 4 | 2022 | 1195 | 0.630 |
Why?
|
| CD40 Antigens | 2 | 2019 | 90 | 0.630 |
Why?
|
| Fluorescent Dyes | 3 | 2021 | 330 | 0.630 |
Why?
|
| Immunologic Memory | 3 | 2021 | 366 | 0.630 |
Why?
|
| Cells | 1 | 2020 | 25 | 0.620 |
Why?
|
| Education | 1 | 2020 | 104 | 0.600 |
Why?
|
| Algorithms | 6 | 2021 | 1839 | 0.600 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 226 | 0.600 |
Why?
|
| Phosphorylation | 11 | 2022 | 1733 | 0.590 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2023 | 147 | 0.590 |
Why?
|
| Computational Biology | 4 | 2017 | 681 | 0.590 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 735 | 0.590 |
Why?
|
| CD40 Ligand | 1 | 2019 | 40 | 0.580 |
Why?
|
| Nestin | 1 | 2018 | 19 | 0.560 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 128 | 0.540 |
Why?
|
| Glossectomy | 1 | 2017 | 1 | 0.520 |
Why?
|
| Facial Recognition | 1 | 2017 | 35 | 0.510 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2016 | 264 | 0.510 |
Why?
|
| Patient Positioning | 1 | 2017 | 70 | 0.510 |
Why?
|
| Phenotype | 9 | 2022 | 3164 | 0.500 |
Why?
|
| Smartphone | 1 | 2017 | 102 | 0.490 |
Why?
|
| Posture | 1 | 2017 | 196 | 0.480 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 154 | 0.480 |
Why?
|
| Virtual Reality | 1 | 2017 | 77 | 0.480 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1322 | 0.470 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 87 | 0.460 |
Why?
|
| MAP Kinase Signaling System | 4 | 2016 | 311 | 0.460 |
Why?
|
| Bone Marrow | 2 | 2018 | 306 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2023 | 988 | 0.450 |
Why?
|
| Head and Neck Neoplasms | 4 | 2017 | 562 | 0.430 |
Why?
|
| Simulation Training | 1 | 2017 | 134 | 0.430 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 332 | 0.420 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1982 | 0.420 |
Why?
|
| Models, Theoretical | 1 | 2018 | 582 | 0.420 |
Why?
|
| Neoplastic Stem Cells | 3 | 2015 | 412 | 0.410 |
Why?
|
| Myeloid Cells | 1 | 2014 | 148 | 0.400 |
Why?
|
| HLA-DR Antigens | 3 | 2021 | 220 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2017 | 1462 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 4 | 2017 | 132 | 0.380 |
Why?
|
| Oxidation-Reduction | 2 | 2015 | 1087 | 0.370 |
Why?
|
| Cell Line, Tumor | 10 | 2026 | 3550 | 0.360 |
Why?
|
| Metabolomics | 3 | 2024 | 727 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 970 | 0.350 |
Why?
|
| Endoscopy | 1 | 2014 | 316 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2025 | 917 | 0.350 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2015 | 80 | 0.340 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2012 | 642 | 0.340 |
Why?
|
| Lateral Ventricles | 2 | 2023 | 32 | 0.340 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 2197 | 0.330 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2023 | 389 | 0.330 |
Why?
|
| Macrolides | 2 | 2024 | 69 | 0.330 |
Why?
|
| Software | 4 | 2023 | 692 | 0.330 |
Why?
|
| Databases as Topic | 1 | 2010 | 71 | 0.320 |
Why?
|
| Internet | 3 | 2015 | 700 | 0.320 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 83 | 0.310 |
Why?
|
| Mouth Neoplasms | 2 | 2026 | 90 | 0.300 |
Why?
|
| Maxillofacial Prosthesis | 1 | 2009 | 1 | 0.300 |
Why?
|
| Maxillary Neoplasms | 1 | 2009 | 8 | 0.300 |
Why?
|
| Maxilla | 1 | 2009 | 36 | 0.300 |
Why?
|
| Phosphoproteins | 3 | 2016 | 346 | 0.300 |
Why?
|
| Gene Expression | 4 | 2016 | 1490 | 0.290 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2006 | 49 | 0.290 |
Why?
|
| Lymphatic Metastasis | 2 | 2026 | 334 | 0.290 |
Why?
|
| Publishing | 1 | 2010 | 114 | 0.290 |
Why?
|
| Lymphocytes | 2 | 2023 | 382 | 0.290 |
Why?
|
| Oximes | 2 | 2018 | 26 | 0.280 |
Why?
|
| Palatine Tonsil | 4 | 2018 | 55 | 0.280 |
Why?
|
| Anemia, Aplastic | 2 | 2020 | 42 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 339 | 0.270 |
Why?
|
| Pyrimidinones | 2 | 2018 | 126 | 0.270 |
Why?
|
| STAT1 Transcription Factor | 3 | 2022 | 68 | 0.260 |
Why?
|
| Aged | 16 | 2026 | 25947 | 0.260 |
Why?
|
| Leukemia | 2 | 2021 | 245 | 0.260 |
Why?
|
| Imidazoles | 2 | 2018 | 254 | 0.250 |
Why?
|
| Pyridones | 2 | 2018 | 199 | 0.250 |
Why?
|
| Cell Communication | 2 | 2024 | 324 | 0.250 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 56 | 0.240 |
Why?
|
| Theranostic Nanomedicine | 1 | 2026 | 15 | 0.240 |
Why?
|
| Porphyrins | 1 | 2026 | 16 | 0.240 |
Why?
|
| Female | 29 | 2026 | 78376 | 0.240 |
Why?
|
| Cells, Cultured | 8 | 2021 | 4155 | 0.240 |
Why?
|
| Carcinogenesis | 2 | 2019 | 229 | 0.240 |
Why?
|
| Middle Aged | 17 | 2026 | 35928 | 0.240 |
Why?
|
| DNA Damage | 3 | 2023 | 430 | 0.240 |
Why?
|
| Animals | 21 | 2026 | 38109 | 0.240 |
Why?
|
| Tyrosine | 1 | 2006 | 222 | 0.230 |
Why?
|
| Adult | 16 | 2026 | 40506 | 0.230 |
Why?
|
| Thyroidectomy | 1 | 2026 | 91 | 0.230 |
Why?
|
| Watchful Waiting | 1 | 2026 | 89 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 241 | 0.220 |
Why?
|
| Multimodal Imaging | 1 | 2026 | 129 | 0.220 |
Why?
|
| Forkhead Transcription Factors | 2 | 2024 | 202 | 0.220 |
Why?
|
| Filipin | 1 | 2024 | 4 | 0.220 |
Why?
|
| Actinobacteria | 1 | 2024 | 17 | 0.220 |
Why?
|
| Young Adult | 8 | 2021 | 14126 | 0.220 |
Why?
|
| Male | 24 | 2026 | 72406 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 919 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 676 | 0.210 |
Why?
|
| Fluorescence | 3 | 2019 | 161 | 0.210 |
Why?
|
| Structure-Activity Relationship | 1 | 2025 | 570 | 0.210 |
Why?
|
| Molecular Structure | 1 | 2025 | 501 | 0.210 |
Why?
|
| Cell Line | 3 | 2021 | 2882 | 0.200 |
Why?
|
| Apoptosis | 4 | 2020 | 2430 | 0.200 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1129 | 0.200 |
Why?
|
| Heterozygote | 1 | 2024 | 315 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 531 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2020 | 1890 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 2642 | 0.190 |
Why?
|
| Cytokines | 4 | 2022 | 2065 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 29 | 0.180 |
Why?
|
| Small Molecule Libraries | 1 | 2023 | 111 | 0.180 |
Why?
|
| HMGB1 Protein | 1 | 2022 | 51 | 0.180 |
Why?
|
| CD57 Antigens | 1 | 2021 | 18 | 0.180 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 17 | 0.180 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 893 | 0.180 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 138 | 0.180 |
Why?
|
| Thyroid Neoplasms | 1 | 2026 | 346 | 0.180 |
Why?
|
| Leukocyte Common Antigens | 3 | 2016 | 88 | 0.180 |
Why?
|
| STAT5 Transcription Factor | 4 | 2021 | 52 | 0.170 |
Why?
|
| Interleukin-2 | 2 | 2020 | 437 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 139 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2026 | 489 | 0.170 |
Why?
|
| Myositis | 1 | 2022 | 57 | 0.170 |
Why?
|
| CD4 Antigens | 1 | 2021 | 139 | 0.170 |
Why?
|
| Microscopy | 1 | 2023 | 156 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 171 | 0.170 |
Why?
|
| Mutation | 5 | 2024 | 4099 | 0.170 |
Why?
|
| Glutaminase | 1 | 2021 | 11 | 0.170 |
Why?
|
| Lipids | 1 | 2026 | 710 | 0.170 |
Why?
|
| Rhinovirus | 1 | 2021 | 57 | 0.170 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2021 | 48 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 168 | 0.160 |
Why?
|
| Histones | 2 | 2023 | 670 | 0.160 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 21 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2017 | 11695 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3415 | 0.160 |
Why?
|
| Prognosis | 5 | 2022 | 4293 | 0.160 |
Why?
|
| Fas Ligand Protein | 1 | 2020 | 60 | 0.160 |
Why?
|
| CD28 Antigens | 1 | 2020 | 58 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2022 | 285 | 0.160 |
Why?
|
| Nephritis | 1 | 2020 | 22 | 0.160 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 264 | 0.160 |
Why?
|
| Tomography, Optical | 1 | 2019 | 3 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2026 | 520 | 0.150 |
Why?
|
| Hydrogen Peroxide | 2 | 2015 | 336 | 0.150 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 206 | 0.150 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 30 | 0.150 |
Why?
|
| Automation | 1 | 2020 | 102 | 0.150 |
Why?
|
| Mice | 9 | 2026 | 18365 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 241 | 0.150 |
Why?
|
| Equipment Design | 2 | 2019 | 530 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 1126 | 0.150 |
Why?
|
| Quality of Life | 2 | 2026 | 3192 | 0.150 |
Why?
|
| Lung | 3 | 2025 | 4109 | 0.150 |
Why?
|
| Tomography | 1 | 2019 | 45 | 0.150 |
Why?
|
| Adenoids | 1 | 2018 | 12 | 0.140 |
Why?
|
| Dexamethasone | 1 | 2021 | 372 | 0.140 |
Why?
|
| Tuberous Sclerosis | 1 | 2019 | 56 | 0.140 |
Why?
|
| Cell Separation | 2 | 2017 | 307 | 0.140 |
Why?
|
| Antibodies, Neoplasm | 1 | 2018 | 35 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 70 | 0.140 |
Why?
|
| RNA, Viral | 1 | 2022 | 688 | 0.140 |
Why?
|
| Disease Progression | 4 | 2016 | 2852 | 0.140 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 139 | 0.140 |
Why?
|
| Astrocytoma | 1 | 2019 | 129 | 0.140 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2017 | 8 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 444 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 672 | 0.140 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 234 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 1990 | 0.130 |
Why?
|
| Biomarkers | 5 | 2022 | 4275 | 0.130 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2017 | 51 | 0.130 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 19 | 0.130 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 166 | 0.130 |
Why?
|
| Proteins | 2 | 2019 | 1022 | 0.130 |
Why?
|
| Hemangiosarcoma | 1 | 2017 | 23 | 0.130 |
Why?
|
| Immunoglobulin M | 3 | 2022 | 284 | 0.130 |
Why?
|
| Scalp | 1 | 2017 | 37 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 32 | 0.120 |
Why?
|
| Jurkat Cells | 1 | 2016 | 114 | 0.120 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 206 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2017 | 101 | 0.120 |
Why?
|
| Antigens, CD | 2 | 2016 | 555 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 162 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2016 | 2 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2019 | 662 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 199 | 0.120 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 76 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2017 | 110 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 847 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2023 | 931 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 412 | 0.120 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2015 | 17 | 0.120 |
Why?
|
| Genes, MHC Class II | 1 | 2016 | 76 | 0.120 |
Why?
|
| NADP | 1 | 2015 | 55 | 0.120 |
Why?
|
| Neutrophils | 1 | 2022 | 1134 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 5417 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2015 | 10 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 1524 | 0.110 |
Why?
|
| Sepsis | 1 | 2022 | 641 | 0.110 |
Why?
|
| Cetuximab | 1 | 2015 | 111 | 0.110 |
Why?
|
| Electromagnetic Fields | 1 | 2015 | 38 | 0.110 |
Why?
|
| Workload | 1 | 2017 | 170 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 119 | 0.110 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2015 | 70 | 0.110 |
Why?
|
| Immune System | 1 | 2016 | 179 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 509 | 0.110 |
Why?
|
| Cause of Death | 1 | 2017 | 472 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2015 | 118 | 0.110 |
Why?
|
| Cell Differentiation | 3 | 2021 | 2050 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 160 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2019 | 458 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2014 | 38 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 668 | 0.100 |
Why?
|
| Bronchoscopy | 1 | 2015 | 227 | 0.100 |
Why?
|
| Information Dissemination | 2 | 2020 | 223 | 0.100 |
Why?
|
| Oncogenes | 1 | 2014 | 119 | 0.100 |
Why?
|
| Histone Acetyltransferases | 1 | 2014 | 62 | 0.100 |
Why?
|
| Cisplatin | 1 | 2015 | 334 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 198 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2015 | 768 | 0.100 |
Why?
|
| Syk Kinase | 2 | 2016 | 22 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2026 | 7997 | 0.090 |
Why?
|
| Clonal Evolution | 1 | 2013 | 47 | 0.090 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 164 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2012 | 25 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2016 | 138 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1980 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2017 | 1385 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2016 | 175 | 0.090 |
Why?
|
| Free Tissue Flaps | 1 | 2012 | 45 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 222 | 0.090 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 173 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2020 | 521 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 1217 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2004 | 176 | 0.080 |
Why?
|
| CD79 Antigens | 2 | 2022 | 16 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 65 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 100 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 8279 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 120 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2016 | 1742 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 187 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 847 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2009 | 23 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2004 | 358 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 5 | 2015 | 1054 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 1786 | 0.070 |
Why?
|
| Calibration | 2 | 2019 | 151 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2015 | 1126 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 433 | 0.070 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 132 | 0.070 |
Why?
|
| Asthma | 1 | 2021 | 1768 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 415 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2008 | 4 | 0.070 |
Why?
|
| Lymph Nodes | 2 | 2026 | 502 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 19 | 0.070 |
Why?
|
| Glycolysis | 2 | 2021 | 340 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2017 | 1244 | 0.070 |
Why?
|
| Phantoms, Imaging | 2 | 2019 | 158 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 848 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 312 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2026 | 6053 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 194 | 0.070 |
Why?
|
| Disease | 1 | 2009 | 98 | 0.070 |
Why?
|
| Osteotomy | 1 | 2009 | 127 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2499 | 0.070 |
Why?
|
| Prosthesis Implantation | 1 | 2009 | 153 | 0.070 |
Why?
|
| Lymphoma | 1 | 2009 | 233 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 465 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2026 | 343 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2009 | 255 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2023 | 781 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 110 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2009 | 433 | 0.060 |
Why?
|
| Copper Radioisotopes | 1 | 2026 | 4 | 0.060 |
Why?
|
| Rats, Nude | 1 | 2026 | 25 | 0.060 |
Why?
|
| Peptide Mapping | 1 | 2006 | 63 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 464 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 7183 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2025 | 1504 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2185 | 0.060 |
Why?
|
| Chemokine CXCL13 | 1 | 2025 | 15 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 2925 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 1141 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2026 | 162 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1495 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 402 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 22453 | 0.060 |
Why?
|
| Secondary Metabolism | 1 | 2024 | 7 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 570 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 415 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 705 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2004 | 21 | 0.050 |
Why?
|
| Carcinogens, Environmental | 1 | 2004 | 14 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17101 | 0.050 |
Why?
|
| Mitochondria | 2 | 2020 | 984 | 0.050 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 55 | 0.050 |
Why?
|
| Lymphopenia | 1 | 2024 | 65 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2010 | 701 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2738 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2023 | 1718 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 717 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 370 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 3608 | 0.050 |
Why?
|
| ras Proteins | 1 | 2004 | 151 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 460 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2012 | 3676 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2024 | 311 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2024 | 103 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 4569 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2023 | 131 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 197 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 1629 | 0.050 |
Why?
|
| Benzamides | 1 | 2023 | 224 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1540 | 0.050 |
Why?
|
| Calreticulin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Mevalonic Acid | 1 | 2002 | 12 | 0.050 |
Why?
|
| DNA Fingerprinting | 1 | 2002 | 32 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 230 | 0.050 |
Why?
|
| Lovastatin | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 36 | 0.050 |
Why?
|
| Buthionine Sulfoximine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 293 | 0.050 |
Why?
|
| Cell Count | 1 | 2022 | 321 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 220 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2004 | 405 | 0.040 |
Why?
|
| Nomograms | 1 | 2022 | 59 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2022 | 76 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2024 | 744 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 2021 | 26 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 2456 | 0.040 |
Why?
|
| Alternaria | 1 | 2021 | 9 | 0.040 |
Why?
|
| Calgranulin B | 1 | 2021 | 10 | 0.040 |
Why?
|
| Pyroglyphidae | 1 | 2021 | 18 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 623 | 0.040 |
Why?
|
| Cell Death | 1 | 2022 | 383 | 0.040 |
Why?
|
| Listeriosis | 1 | 2021 | 65 | 0.040 |
Why?
|
| Tretinoin | 1 | 2021 | 124 | 0.040 |
Why?
|
| Glutamine | 1 | 2021 | 109 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 174 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 65 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 758 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 215 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2020 | 39 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 1026 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 357 | 0.040 |
Why?
|
| Glutathione | 1 | 2002 | 375 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 171 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 101 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 116 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 210 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 19 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 69 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 498 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 1500 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 930 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 369 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2023 | 619 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2019 | 67 | 0.040 |
Why?
|
| Linear Models | 1 | 2022 | 854 | 0.040 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2019 | 16 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1465 | 0.040 |
Why?
|
| Pyridines | 1 | 2023 | 605 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 621 | 0.040 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2002 | 269 | 0.040 |
Why?
|
| Software Validation | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 5997 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 610 | 0.040 |
Why?
|
| Rabbits | 1 | 2019 | 648 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 424 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 636 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 439 | 0.030 |
Why?
|
| Streptomyces | 1 | 2018 | 9 | 0.030 |
Why?
|
| Cell Extracts | 1 | 2018 | 21 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2022 | 780 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 129 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2020 | 379 | 0.030 |
Why?
|
| Salivary Glands | 1 | 1998 | 36 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 143 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 100 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 268 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2015 | 1486 | 0.030 |
Why?
|
| Pharynx | 1 | 1998 | 59 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 1998 | 88 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 5872 | 0.030 |
Why?
|
| Rats | 1 | 2026 | 5614 | 0.030 |
Why?
|
| Recurrence | 2 | 2013 | 1135 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 348 | 0.030 |
Why?
|
| Carrier State | 1 | 1998 | 79 | 0.030 |
Why?
|
| Ontario | 1 | 2017 | 96 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 49 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 28 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 48 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 33 | 0.030 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2016 | 11 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2017 | 79 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2016 | 62 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 3869 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 489 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Protein Binding | 2 | 2014 | 2276 | 0.030 |
Why?
|
| fas Receptor | 1 | 2016 | 92 | 0.030 |
Why?
|
| Lanthanoid Series Elements | 1 | 2015 | 2 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 75 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 454 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 266 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2016 | 151 | 0.030 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2015 | 69 | 0.030 |
Why?
|
| Pleura | 1 | 2015 | 28 | 0.030 |
Why?
|
| Indocyanine Green | 1 | 2015 | 42 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2019 | 583 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 769 | 0.030 |
Why?
|
| Stem Cells | 1 | 2019 | 627 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2015 | 50 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 34 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1049 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 418 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 34 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 28 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 197 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 966 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 269 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 1187 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 322 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 437 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1311 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 384 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2017 | 5965 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 2947 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1268 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 710 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1958 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 73 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1325 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 336 | 0.020 |
Why?
|
| Bronchi | 1 | 2015 | 267 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 364 | 0.020 |
Why?
|
| Histiocytes | 1 | 2013 | 7 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2013 | 30 | 0.020 |
Why?
|
| E-Selectin | 1 | 2013 | 61 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 476 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 266 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 6434 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2012 | 17 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2018 | 1813 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2013 | 206 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 227 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 481 | 0.020 |
Why?
|
| Child | 4 | 2019 | 22657 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 248 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2609 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 310 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 1835 | 0.020 |
Why?
|
| Chromatin | 1 | 2015 | 561 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 2330 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 422 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 152 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 381 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 526 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 87 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 550 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 27 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 631 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 29 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2012 | 540 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2385 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 2832 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 161 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2092 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 372 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2019 | 11799 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1253 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 469 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 2032 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 25 | 0.010 |
Why?
|
| Activating Transcription Factors | 1 | 2002 | 3 | 0.010 |
Why?
|
| Diazepam Binding Inhibitor | 1 | 2002 | 2 | 0.010 |
Why?
|
| Phalloidine | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2002 | 3 | 0.010 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2002 | 4 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2002 | 13 | 0.010 |
Why?
|
| Sterols | 1 | 2002 | 21 | 0.010 |
Why?
|
| Coenzyme A Ligases | 1 | 2002 | 15 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 26 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2002 | 74 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2002 | 38 | 0.010 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2002 | 55 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1167 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 2002 | 19 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 43 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 152 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 181 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 347 | 0.010 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2002 | 76 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2002 | 85 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 276 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2002 | 105 | 0.010 |
Why?
|
| Cytosol | 1 | 2002 | 227 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 280 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1822 | 0.010 |
Why?
|
| United States | 1 | 2018 | 15988 | 0.010 |
Why?
|
| Protein Transport | 1 | 2002 | 441 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2002 | 249 | 0.010 |
Why?
|
| Cholesterol | 1 | 2002 | 408 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 1095 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 675 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 1098 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 2118 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 597 | 0.010 |
Why?
|
| Parotid Gland | 1 | 1998 | 17 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 1258 | 0.010 |
Why?
|